Endymed Valuation
| ENDY Stock | 302.00 11.90 4.10% |
At this time, the firm appears to be overvalued. Endymed shows a prevailing Real Value of 233.9 per share. The current price of the firm is 302.0. Our model computes the value of Endymed from reviewing the firm fundamentals such as Operating Margin of 0.06 %, current valuation of 1.85 M, and Profit Margin of 0.14 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Endymed's price fluctuation is very steady at this time. Calculation of the real value of Endymed is based on 3 months time horizon. Increasing Endymed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Endymed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Endymed Stock. However, Endymed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 302.0 | Real 233.9 | Hype 302.0 | Naive 275.03 |
The real value of Endymed Stock, also known as its intrinsic value, is the underlying worth of Endymed Company, which is reflected in its stock price. It is based on Endymed's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Endymed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Endymed helps investors to forecast how Endymed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Endymed more accurately as focusing exclusively on Endymed's fundamentals will not take into account other important factors: Endymed Total Value Analysis
Endymed is currently forecasted to have takeover price of 1.85 M with market capitalization of 35.42 M, debt of 463 K, and cash on hands of 5.02 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Endymed fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.85 M | 35.42 M | 463 K | 5.02 M |
Endymed Investor Information
About 58.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. Endymed had not issued any dividends in recent years. The entity had 1:20 split on the 28th of January 2018. Based on the measurements of operating efficiency obtained from Endymed's historical financial statements, Endymed is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Endymed Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Endymed has an asset utilization ratio of 111.16 percent. This suggests that the Company is making 1.11 for each dollar of assets. An increasing asset utilization means that Endymed is more efficient with each dollar of assets it utilizes for everyday operations.Endymed Ownership Allocation
The market capitalization of Endymed is 35.42 Million. Endymed retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with substantial debt, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.Endymed Profitability Analysis
The company reported the revenue of 21.78 M. Net Income was 5.16 M with profit before overhead, payroll, taxes, and interest of 10.06 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Endymed's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Endymed and how it compares across the competition.
About Endymed Valuation
The stock valuation mechanism determines Endymed's current worth on a weekly basis. Our valuation model uses a comparative analysis of Endymed. We calculate exposure to Endymed's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Endymed's related companies.Endymed Ltd, a medical technology company, designs, develops, and commercializes energy based medical aesthetic treatment systems for the professional and consumer markets worldwide. Endymed Ltd was founded in 2007 and is based in New York, New York. ENDYMED LTD operates under Medical Devices classification in Israel and is traded on Tel Aviv Stock Exchange.
8 Steps to conduct Endymed's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Endymed's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Endymed's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Endymed's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Endymed's revenue streams: Identify Endymed's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Endymed's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Endymed's growth potential: Evaluate Endymed's management, business model, and growth potential.
- Determine Endymed's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Endymed's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Endymed Stock analysis
When running Endymed's price analysis, check to measure Endymed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endymed is operating at the current time. Most of Endymed's value examination focuses on studying past and present price action to predict the probability of Endymed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endymed's price. Additionally, you may evaluate how the addition of Endymed to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |